AstraZeneca COVID-19 vaccine
GPTKB entity
Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:antiSubmarineWarfare |
informed consent and access
|
| gptkbp:approves |
gptkb:World_Health_Organization
|
| gptkbp:clinicalTrials |
over 30,000
global Phase III |
| gptkbp:collaboratedWith |
gptkb:University_of_Oxford
|
| gptkbp:communityImpact |
critical in pandemic response
|
| gptkbp:contraindication |
thrombosis
thrombocytopenia |
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:diseaseResistance |
public awareness campaigns
published in medical journals |
| gptkbp:dosageForm |
two doses
|
| gptkbp:emergencyServices |
multiple countries
|
| gptkbp:endOfProduction |
under investigation
billions of doses |
| gptkbp:evaluates |
approximately 76% after two doses
|
| gptkbp:expansion |
yes
|
| gptkbp:firstAwarded |
8 to 12 weeks
|
| gptkbp:foughtAgainst |
reduced efficacy against some variants
|
| gptkbp:hasContribution |
contributes to herd immunity
|
| gptkbp:historicalResearch |
international partnerships
|
| https://www.w3.org/2000/01/rdf-schema#label |
AstraZeneca COVID-19 vaccine
|
| gptkbp:insuranceAccepted |
conducted by health agencies
|
| gptkbp:isConsidered |
yes
|
| gptkbp:isTestedFor |
significant
|
| gptkbp:launchDate |
December 2020
April 2020 |
| gptkbp:marketedAs |
gptkb:Vaxzevria
|
| gptkbp:notable_player |
international
mixed reviews public and private funding various health authorities reduced hospitalization rates non-replicating viral vector ongoing safety monitoring stable at refrigerator temperatures effective against severe disease |
| gptkbp:produces |
multiple countries
|
| gptkbp:providesAccessTo |
generally well tolerated
|
| gptkbp:providesSupportFor |
gptkb:COVAX_Facility
|
| gptkbp:researchContribution |
widely distributed
|
| gptkbp:route |
intramuscular injection
|
| gptkbp:scientificName |
gptkb:AstraZeneca/Oxford_vaccine
|
| gptkbp:sideEffect |
fatigue
headache muscle pain nausea fever |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:targets |
gptkb:COVID-19
adults |
| gptkbp:technology |
recombinant DNA technology
|
| gptkbp:type |
viral vector vaccine
|
| gptkbp:wasAffecting |
February 2021
|